Allergic asthma is a chronic inflammatory lung disease characterized by airway hyper-responsiveness (AHR), excessive mucus production, lung eosinophilia and airway remodeling 1 . Although T H 2 cells have a major role in this disease 2 , the mechanisms underlying their recruitment, reactivation and survival in airways remain unknown.
The chemokine CX3CL1 binds only to and is the unique ligand of CX3CR1, making this ligand-receptor pair an attractive therapeutic target. In humans, CX3CL1 is constitutively expressed by intestinal epithelial cells, synoviocytes, macrophages and dendritic cells (DCs) 3, 4 . CX3CL1 is expressed by endothelial cells upon stimulation by inflammatory cytokines and is upregulated in Crohn's disease 5 , rheumatoid arthritis, atherosclerosis 6 and systemic lupus erythematosus 7 . In both humans and mice, CX3CR1 is expressed by monocytes, macrophages, mucosal DCs, natural killer cells, CD8 + T cells and a subset of effector-memory CD4 + T cells [8] [9] [10] [11] . In humans, most CX3CR1-expressing lymphocytes are T H 1 cells 12, 13 . Because CX3CL1 is upregulated upon inflammation, it has been proposed to contribute to inflammatory diseases by promoting the transmigration of CX3CR1-expressing cells to inflamed tissues. CX3CR1-and CX3CL1-deficient mice do not show gross abnormalities. WT and CX3CL1-deficient mice have similar lymph node cellular composition, and CX3CR1-deficient DCs are not impaired in migration or differentiation in response to microbial antigens or contact sensitizers 10 . However, both CX3CR1-deficient and CX3CL1-deficient mice show reduced atherosclerosis when crossed to mice lacking apolipoprotein E 14 . In addition, a CX3CL1 antagonist delays the initiation of lupus nephritis in the lupus-prone MRL lpr/lpr strain 15 , and antibody to CX3CL1 improves experimental autoimmune myositis in SJL/J mice 16 and collagen-induced arthritis in DBA mice 6 . In individuals with atopic dermatitis, CX3CL1 was expressed by skin lesion endothelial cells, and serum CX3CL1 concentrations were associated with disease severity 17 . In individuals with asthma, a fraction of memory-effector CD4 + T cells expressed CX3CR1, and CX3CL1 expression was increased in airway smooth muscle, lung epithelium and bronchoalveolar lavage fluids (BALF) upon allergen challenge 18, 19 . Furthermore, two CX3CR1 single nucleotide polymorphisms were associated with asthma and atopy in French-Canadian populations 20 and German children 21 . In this study, we seek to investigate the role of CX3CR1 and CX3CL1 in the development of allergic airway inflammation in mice.
RESULTS

CX3CR1 is required for allergic airway inflammation in mice
To investigate the role of CX3CR1 and CX3CL1 in allergic airway inflammation, we used Cx3cr1 GFP/GFP mice in which the two alleles of the Cx3cr1 gene were replaced by the EGFP reporter gene 10 . We sensitized CX3CR1-deficient Cx3cr1 GFP/GFP and their a r t i c l e s 1 3 0 6 VOLUME 16 | NUMBER 11 | NOVEMBER 2010 nature medicine CX3CR1-proficient Cx3cr1 +/+ littermates and challenged them with the Leishmania homolog of receptors for activated C kinase (LACK) antigen. Compared to Cx3cr1 +/+ mice, Cx3cr1 GFP/GFP mice showed reduced AHR (Fig. 1a) , fewer total cells and eosinophils in BALF ( Fig. 1b) , reduced lung infiltrates ( Fig. 1c) and decreased mucus secretion (Fig. 1d) . The lungs of Cx3cr1 GFP/GFP mice contained lower T H 2 cytokine amounts than those of Cx3cr1 +/+ mice (Fig. 1e) . Interferon-γ (IFN-γ) amounts remained low in both groups (Fig. 1e) . Interleukin-4 (IL-4)-and IL-5-secreting CD4 + T cell numbers in the lung were lower in Cx3cr1 GFP/GFP mice than in Cx3cr1 +/+ mice ( Fig. 1f) .
We obtained similar results upon ovalbumin (OVA) ( Supplementary  Fig. 1 ), ragweed ( Supplementary Fig. 2 ) and house dust mite (HDM) ( Supplementary Fig. 3 ) sensitization and challenge. Of note, Cx3cr1 +/GFP and Cx3cr1 +/+ mice developed similar airway inflammation ( Supplementary Fig. 4 ).
To confirm the role of CX3CR1 in airway inflammation, we treated WT mice with a CX3CR1-blocking antibody or the CX3CL1 antagonist FKN-AT 15 (Fig. 2a) . We sensitized mice with LACK, treated them with CX3CR1-blocking antibody or FKN-AT or left them untreated, and then exposed them to LACK aerosols. Compared to controls, prophylactic treatment with either FKN-AT or antibody to CX3CR1 decreased LACK-induced AHR (Fig. 2b,c) , airway inflammation and eosinophilia ( Fig. 2d ) and impaired IL-4, IL-5 and IL-13 secretion by lung CD4 + T cells ( Fig. 2e) . FKN-AT was also protective when given as a curative treatment ( Fig. 2b,d,e ). Altogether, these data show that CX3CR1 and CX3CL1 are required for optimal disease development.
CX3CR1 expression by CD4 + T cells is required for asthma
We next investigated whether Cx3cr1 GFP/GFP mice were impaired in their CD4 + T cell response. Mediastinal lymph node cells from LACKimmunized WT and Cx3cr1 GFP/GFP mice secreted similar IL-4, IL-5, IL-10, IL-13 and IFN-γ amounts, suggesting that CD4 + T cell responses were not impaired in Cx3cr1 GFP/GFP mice (Supplementary Fig. 5 ).
We next compared the ability of CD4 + T cells from CX3CR1deficient and CX3CR1-proficient mice to restore airway inflammation when injected into CX3CR1-deficient mice. In contrast to Cx3cr1 GFP/GFP cells, WT CD4 + T cells restored AHR and eosinophilia in Cx3cr1 GFP/GFP mice ( Fig. 3a,b) . To confirm this result, we injected Cx3cr1 GFP/GFP mice with CX3CR1-proficient LACK-specific T H 2 cells, treated with FKN-AT or left untreated and exposed to LACK. Both AHR and eosinophilia were reduced in FKN-AT-treated mice compared to controls ( Fig. 3c,d) . Both the frequency of donor cells and T H 2 cytokine secretion were reduced upon treatment with FKN-AT ( Fig. 3e,f) . Therefore, CX3CR1 expression by T H 2 cells is required for the optimal development of airway disease.
T H 2 cells express CX3CR1 in the airways
We monitored CX3CR1 expression in Cx3cr1 +/GFP mice, using GFP as a surrogate marker for CX3CR1 expression 9, 10 . As previously reported 10 , the frequency of GFP + CD4 + T cells in naive Cx3cr1 +/GFP mice was lower than 0.5% in blood, spleen, mesenteric lymph node (MLN), lung and BALF (Fig. 4a ). This frequency slightly increased in all compartments after LACK sensitization and increased even further after challenge in lung and BALF. We obtained similar data in OVA-sensitized and challenged Cx3cr1 +/GFP mice (Supplementary Fig. 6 ). Quantitative PCR confirmed that BALF and lung CD4 + T cells expressed higher levels of Cx3cr1 mRNA than CD4 + T cells from spleen and MLN in LACK sensitized and challenged WT mice ( Fig. 4b) .
We further analyzed airway-infiltrating T cells for expression of the T H 2-specific marker T1/ST2. In lung and BALF, 18% and 25% of CD4 + T cells were T1/ST2 + (Fig. 4c) . Furthermore, 20% and 27% of lung and BALF T1/ST2 + cells were GFP + (Fig. 4c) , indicating that 20-30% of T H 2 cells in inflamed airways expressed CX3CR1. Likewise, lung GFP + cells were enriched in T H 2 cytokine-secreting cells, as indicated by both intracellular cytokine staining and supernatant analysis after restimulation of purified GFP + cells ( Fig. 4d) . Indeed, the percentage of IL-5-and IL-13-producing CD4 + T cells in lung that also expressed CX3CR1 was 25%. GFP + CD4 + cells also expressed higher levels of mRNAs coding for CCR8, CXCR4, IL-4, IL-5, IL-10 and IL-13 than GFP − CD4 + cells ( Supplementary Fig. 7) . Altogether, these data suggested that CX3CR1-expressing CD4 + cells are enriched in T H 2 effector cells.
CX3CR1 provides a selective advantage to T H 2 cells
The key role of CX3CR1 in airway inflammation and the presence of CX3CR1 + CD4 + T cells in the airways could reflect the preferential migration of CX3CR1 + CD4 + cells to the airways, the ability of the lung tissue to induce or maintain CX3CR1 expression by T H 2 cells, a selective advantage conferred by CX3CR1 on the maintenance of T H 2 cells or a combination of the above mechanisms. To address these issues, we generated Thy1 a/b Cx3cr1 +/GFP and Thy1 a/a Cx3cr1 GFP/GFP WT15 T cell receptor (TCR)-transgenic mice that respectively expressed the Thy1.1 and Thy1.2 antigens or the Thy1.1 antigen only and differentiated their CD4 + T cells ex vivo into T H 2 cells. Both populations were GFP − after differentiation and secreted similar amounts of cytokines, indicating that CX3CR1-deficient T H 2 cells had no intrinsic defect in cytokine secretion (Supplementary Fig. 8a-c) .
In addition, CX3CR1-deficient and CX3CR1-proficient T H 2 cells showed similar FACS profiles upon staining with antibodies to CD69, CD25, CD44 and CD62 ligand ( Supplementary Fig. 8d ). We injected equal numbers of CX3CR1-proficient and CX3CR1-deficient T H 2 cells into Thy1 b/b WT mice that we then exposed to LACK. Before antigen exposure, CX3CR1-deficient and CX3CR1-proficient donor cells were present at the same low frequency in all tissues, suggesting that the homing of CX3CR1-deficient T cells to lymphoid and nonlymphoid organs in steady-state conditions was not altered ( Fig. 5a and Supplementary Fig. 9 ). The frequency of both CX3CR1-deficient and CX3CR1-proficient donor cells rapidly increased in lung but not in mediastinal lymph node after the first aerosol challenge. After the third aerosol challenge, both populations were detectable in BALF, and their frequency further increased in lung and MLN, but not in spleen ( Fig. 5a and Supplementary Fig. 9 ). Furthermore, although both T H 2 populations were found at the same low frequency in lung, BALF, peripheral lymph node (PLN) and spleen, CX3CR1-proficient T H 2 cells outnumbered CX3CR1-deficient T H 2 cells in MLN. After the fifth aerosol challenge, CX3CR1-proficient T H 2 cells outnumbered CX3CR1-deficient T H 2 cells in BALF, lung and MLN but not in PLN or spleen. Therefore, CX3CR1-proficient T H 2 cells have a selective advantage compared to CX3CR1-deficient T H 2 cells, resulting in their preferential expansion or maintenance in the MLN and the inflamed lung.
Before and after the first aerosol, both CX3CR1-deficient and CX3CR1-proficient T H 2 cells remained GFP − (Fig. 5b) . After the third aerosol, both populations expressed GFP in BALF, lung, MLN and spleen (Fig. 5b) . GFP expression in lung and BALF remained high after the fourth and fifth aerosols but decreased in both MLN and spleen to background level (Fig. 5b) . To elucidate how CX3CR1 expression is regulated, we injected equal numbers of both CX3CR1proficient and CX3CR1-deficient LACK-specific T H 2 cells into OVAsensitized and challenged mice and into OVA-sensitized recipients that were exposed to OVA and LACK. As expected, all recipients showed airway inflammation, and CX3CR1-proficient cells outnumbered CX3CR1-deficient cells in lung and BALF of mice exposed to both OVA and LACK (Fig. 5c) . In contrast, we found both populations at a similar frequency in the inflamed lung and BALF of mice challenged with OVA only (Fig. 5c) . Therefore, CX3CR1-proficient and CX3CR1-deficient LACK-specific T H 2 cells were equally capable of migrating to the inflamed lung, suggesting that T H 2 cells were recruited to the airways through a CX3CR1-independent mechanism. Whereas both CX3CR1-proficient and CX3CR1-deficient T H 2 cells in BALF and lung expressed GFP in mice exposed to OVA and LACK, both populations remained GFP − in mice exposed to OVA only (Fig. 5d) . Therefore, inflammation was not sufficient to induce infiltrating T H 2 cells to express CX3CR1 but CX3CR1 upregulation required TCR engagement.
CX3CR1 provides a survival signal to lung T H 2 cells
To compare the ability of CX3CR1-deficient and CX3CR1-proficient LACK-specific T H 2 cells to proliferate in vivo, we injected equal numbers of these cells into recipients that were then exposed to LACK and treated with BrdU. Both populations proliferated similarly (Supplementary Fig. 10a ). We next monitored the death of T H 2 donor cells in vivo. In lung and MLN, the frequencies of both TUNEL + and 7-aminoactinomycin D (7-AAD) + cells were higher among CX3CR1deficient cells than among CX3CR1-proficient cells ( Fig. 6a and Supplementary Fig. 10b) . In contrast, we saw no difference in the PLN. To confirm these data, we monitored the death of endogenous GFP + CD4 + T cells in sensitized and challenged mice. Whereas 26.8 ± 0.8% of GFP + cells were 7-AAD + in Cx3cr1 +/GFP mice, this frequency increased to 42.6 ± 1.1% in Cx3cr1 GFP/GFP mice (Supplementary Fig. 11) . Therefore, CX3CR1-deficient T helper cells were more susceptible to death than CX3CR1proficient T helper cells. We next monitored the death of CX3CR1-deficient and CX3CR1proficient T H 2 cells that had been induced to express GFP upon incubation with lung cells. We incubated sorted GFP − and GFP + cells without serum to induce cell death in the presence or absence of CX3CL1. Most GFP + and GFP − CX3CR1-deficient cells as well as most GFP − CX3CR1-proficient cells died, as indicated by the high frequency of 7-AAD + cells, irrespective of the presence of CX3CL1 (Supplementary Fig. 12) . In contrast, the frequency of GFP + CX3CR1-proficient cells that died upon serum deprivation decreased from 72% to 26% upon addition of CX3CL1 (Supplementary Fig. 12 ). Therefore, CX3CR1 provided a survival signal to T H 2 cells. The frequency of 7-AAD + cells was also decreased by the addition of either CXCL12 or CCL22, but this effect was similar in all populations irrespective of CX3CR1 expression ( Supplementary Fig. 12) .
We next investigated whether the increased sensitivity to apoptosis of CX3CR1-deficient T H 2 cells accounted for their rapid disappearance from the lungs in asthmatic mice. We infected CX3CR1-deficient and CX3CR1-proficient LACK-specific T H 2 cells with a retroviral vector carrying the genes encoding antiapoptotic BCL-2 and GFP (BCL-2 vector) or only GFP (empty vector). We sorted GFP + infected cells. This was possible because neither CX3CR1-deficient nor CX3CR1-proficient T H 2 cells expressed GFP after in vitro differentiation. Infected CX3CR1-deficient and CX3CR1-proficient LACK-specific cells were either incubated without serum or co-injected into CX3CR1-deficient mice that were then challenged with LACK. As expected, CX3CR1-deficient cells were partially rescued from serum deprivation-induced apoptosis when infected with the BCL-2-transducing retroviral vector but not with the empty vector (Supplementary Fig. 13 ). Upon injection into recipients, and in agreement with data obtained with uninfected cells, CX3CR1-proficient cells infected with the empty vector outnumbered CX3CR1-deficient cells infected with the same virus in MLN after the third aerosol and in both lung and MLN after the fifth aerosol (Fig. 6b) . In contrast, BCL-2-transduced CX3CR1-deficient cells were present at the same frequency as CX3CR1-proficient cells in MLN after the third aerosol and in lung after the fifth aerosol (Fig. 6b) . BCL-2-transduced CX3CR1-deficient cells even outnumbered CX3CR1-proficient cells in MLN after the fifth aerosol (Fig. 6b) . Therefore, BCL-2 rescued CX3CR1-deficient T H 2 cells from apoptosis in vivo. Together, our data demonstrate that CX3CR1-deficient T H 2 cells show an increased sensitivity to apoptosis, therefore accounting for their disappearance from the airways of allergen-sensitized, challenged mice. To further investigate how the increased sensitivity to death of CX3CR1-deficient T H 2 cells affects allergic airway disease, we injected CX3CR1-deficient LACK-specific T H 2 cells infected with the BCL-2-encoding vector or the empty vector into Cx3cr1 GFP/GFP mice that were next exposed to LACK aerosols. As controls, Cx3cr1 GFP/GFP mice received CX3CR1-proficient T H 2 cells infected with the empty vector (Fig. 6c) . When infected with the empty vector, CX3CR1-proficient T H 2 cells induced a more severe airway inflammation in Cx3cr1 GFP/GFP mice than did CX3CR1deficient T H 2 cells (Fig. 6c) . In contrast, Cx3cr1 GFP/GFP mice injected with BCL-2-transduced CX3CR1-deficient T H 2 cells developed similar airway inflammation as those injected with CX3CR1proficient T H 2 cells (Fig. 6c) . Taken together, our results show that CX3CR1 provides a survival signal to T H 2 cells that is required for airway disease. CXCR1-independent maintenance in steady-state and inflamed PLN We next investigated whether CX3CR1 increased T H 2 cell survival in general or only in the inflamed airways. We injected equal numbers of CX3CR1-deficient and CX3CR1-proficient T H 2 cells into naive mice and monitored the frequency of each population 1 and 3 weeks later. The survival rate of these two populations was similar, suggesting that CX3CR1 is not involved in T H 2 cell maintenance under homeostatic conditions (Fig. 6d) . Mice were also co-injected with CX3CR1deficient and CX3CR1-proficient T H 2 cells and further immunized subcutaneously with LACK in CFA or CFA only. Although both populations were detected in inflamed lymph node, mice immunized with LACK in CFA had more donor cells in lymph node than those immunized with CFA only (Fig. 6e) .
In contrast to what we had observed in inflamed airways, CX3CR1-deficient and CX3CR1-proficient donor T H 2 cells were present at the same frequency in inflamed LN in both groups. Therefore, while CX3CR1 provided a survival signal to T H 2 cells in inflamed airways, it did not increase T H 2 cell survival in inflamed popliteal lymph node.
Previous studies have shown that T H 1 cells induce airway inflammation but not eosinophilia upon injection into recipients and aerosolized antigen challenge 22 . We used this model to investigate whether CX3CR1 provided a survival signal to T H 1 cells, as it did for T H 2 cells. We differentiated CX3CR1-proficient and CX3CR1-deficient LACKspecific T cells into T H 1 cells. Both populations remained GFP − and showed similar FACS profiles after intracellular cytokine staining and staining with antibodies to CD62 ligand, CD44, CD25 and CD69 (Supplementary Fig. 14a-c) . We then injected equal numbers of these cells into recipients that we next exposed to LACK. Before antigen exposure, we found CX3CR1-deficient and CX3CR1-proficient donor T H 1 cells at the same low frequencies in all tissues (Fig. 6f) . After the first aerosol, the frequency of both populations rapidly increased in lung, MLN and spleen but not in PLN (Fig. 6f) . After the third aerosol, the frequency of both populations further increased in MLN but not in other organs (Fig. 6f) . Furthermore, although we found the two populations at the same low frequency in PLN, CX3CR1-proficient T H 1 cells outnumbered CX3CR1-deficient T H 1 cells in MLN, lung, BALF and spleen (Fig. 6f) . After the fifth aerosol, the frequency of both populations decreased in lung, with CX3CR1-proficient T H 1 cells outnumbering CX3CR1-deficient cells T H 1 in BALF, lung and MLN (Fig. 6f) . Further experiments showed that CX3CR1-deficient and CX3CR1-proficient T H 1 cells proliferated similarly in vivo and that CX3CR1 protected CX3CR1-proficient T H 1 cells from serum deprivation-induced cell death in vitro (Supplementary Fig. 14d,e) . Together, our results show that CX3CR1 confers a survival advantage on both T H 1 and T H 2 cells in inflamed airways but not under homeostatic conditions or in inflamed PLN.
DISCUSSION
The role of chemokine receptors has previously been investigated in animal models of asthma. For example, targeted deletion of the genes encoding CCR3 or CCR4 in mice did not inhibit asthma 23, 24 , and neutralization of CCR4 in guinea pig did not prevent cell recruitment to the lung 25 . In apparent contrast, neutralization of the CCR4 ligand CCL17 decreased AHR and T H 2 cytokine amounts 26 , and CCR4 was shown to be required for T H 2 entry into the lung in mice 27 . CCR8 was dispensable in two studies but not in others [27] [28] [29] [30] . CXCR4 was required for airway inflammation, but it was not clear whether its expression was required on T cells or other cells 31, 32 . These studies suggested that chemokine receptors could play a part in airway inflammation, but it was not clear on which cell types they are required.
Here we have shown that CX3CR1-deficient mice show reduced AHR, eosinophilia, mucus secretion and T H 2 cytokine levels compared to their littermates in whom neither or only one of the two Cx3cr1 alleles was disrupted. This was shown in mice sensitized and challenged with LACK, OVA, HDM or ragweed. In addition, blocking CX3CR1-CX3CL1 interactions with either a CX3CR1-specific antibody or a CX3CL1 antagonist prevented airway inflammation in WT mice. CD4 + T cells purified from WT mice, but not from CX3CR1-deficient mice, restored lung inflammation when injected into CX3CR1-deficient mice, demonstrating that CX3CR1 expression by T H 2 cells is essential for disease. Furthermore, treatment with FKN-AT inhibited disease in CX3CR1-deficient mice injected with CX3CR1-proficient T H 2 cells.
Although in initial studies chemokines were shown to induce chemotaxis in vitro, they also have a role in angiogenesis, tissue repair, tumor progression, hematopoiesis, antimicrobial mechanisms and pain control [33] [34] [35] [36] [37] [38] [39] [40] [41] . In addition to its role in chemotaxis and adhesion 8 , CX3CL1 acts as a survival factor for microglial cells and monocytes 42, 43 . Here we have shown that CX3CR1 is dispensable for T cell migration to the lung but required for T cell maintenance and survival in inflamed airways. In contrast, T cell survival under homeostatic conditions or in inflamed PLN was CX3CR1 independent. It remains to be determined which factors induce T helper cells to express CX3CR1 in vivo and the survival signals that are induced by the binding of CX3CL1 to CX3CR1.
A fraction of memory-effector peripheral CD4 + T cells express CX3CR1 in humans 13, 18 . In one study, human CX3CR1 + CD4 + T cells expressed CCR5, suggesting that they were T H 1 cells 13 . Likewise, human polarized T H 1 cells expressed a high level of Cx3cr1 mRNA, whereas polarized T H 2 cells did not 12 . In mice in our study, we found that neither T H 1 nor T H 2 in vitro-differentiated cells expressed CX3CR1 unless incubated with lung cells or injected into sensitized mice exposed to aerosols of their cognate antigen. Therefore, CX3CR1 expression was inducible in T helper cells. This also explains why CX3CR1 is not required for T helper cell survival under homeostatic conditions and T helper cell recruitment to inflamed lymph nodes. Of note, three promoter regions control the human CX3CR1 gene, leading to the transcription of several mature mRNAs 44 . This highly complex regulation may allow versatile and tightly regulated CX3CR1 expression in different cell types. IL-2 induces CX3CR1 on both human peripheral blood mononuclear cells and mouse splenocytes, and transforming growth factor-β1, IL-10 and IFN-γ upregulate CX3CR1 on rat microglial and monocytic cells 45, 46 . It is unknown whether any of these cytokines induce T helper cells to express CX3CR1 in airways.
Although asthma is a paradigm for T H 2-driven inflammation, concomitant T H 1 activation has been observed in humans [47] [48] [49] , and the presence of T H 1 cells in sputum correlated with both the loss of asthma control and exacerbations 50 . Therefore, our results showing that CX3CR1 and CX3CL1 are required for the survival of both T H 1 and T H 2 cells in inflamed airways makes these molecules interesting therapeutic targets. In addition, the fact that CX3CL1 antagonist was protective when administered intranasally is particularly promising, because corticosteroids and β2-agonist bronchodilators that constitute the standard therapy of asthma are given as inhaled drugs. Furthermore, although inhaled corticosteroids are very effective, they have side effects, and 10% of patients with asthma do not respond to this treatment 51 . More specific therapeutic agents such as antibodies to IL-5 or IgE have been tested in clinical trials but the results have been disappointing 52 . As there is an urgent need for better therapy, blocking CX3CR1 signaling may represent a promising alternative therapy.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
